...
首页> 外文期刊>BMC Neurology >Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats
【24h】

Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats

机译:低剂量静注美满霉素对大鼠大脑中动脉闭塞-再灌注后的神经保护作用

获取原文

摘要

Background Minocycline, a semi-synthetic tetracycline antibiotic, is an effective neuroprotective agent in animal models of cerebral ischemia when given in high doses intraperitoneally. The aim of this study was to determine if minocycline was effective at reducing infarct size in a Temporary Middle Cerebral Artery Occlusion model (TMCAO) when given at lower intravenous (IV) doses that correspond to human clinical exposure regimens. Methods Rats underwent 90 minutes of TMCAO. Minocycline or saline placebo was administered IV starting at 4, 5, or 6 hours post TMCAO. Infarct volume and neurofunctional tests were carried out at 24 hr after TMCAO using 2,3,5-triphenyltetrazolium chloride (TTC) brain staining and Neurological Score evaluation. Pharmacokinetic studies and hemodynamic monitoring were performed on minocycline-treated rats. Results Minocycline at doses of 3 mg/kg and 10 mg/kg IV was effective at reducing infarct size when administered at 4 hours post TMCAO. At doses of 3 mg/kg, minocycline reduced infarct size by 42% while 10 mg/kg reduced infarct size by 56%. Minocycline at a dose of 10 mg/kg significantly reduced infarct size at 5 hours by 40% and the 3 mg/kg dose significantly reduced infarct size by 34%. With a 6 hour time window there was a non-significant trend in infarct reduction. There was a significant difference in neurological scores favoring minocycline in both the 3 mg/kg and 10 mg/kg doses at 4 hours and at the 10 mg/kg dose at 5 hours. Minocycline did not significantly affect hemodynamic and physiological variables. A 3 mg/kg IV dose of minocycline resulted in serum levels similar to that achieved in humans after a standard 200 mg dose. Conclusions The neuroprotective action of minocycline at clinically suitable dosing regimens and at a therapeutic time window of at least 4–5 hours merits consideration of phase I trials in humans in view of developing this drug for treatment of stroke.
机译:背景技术米诺环素是一种半合成的四环素抗生素,当腹膜内高剂量给予时,在脑缺血的动物模型中是一种有效的神经保护剂。这项研究的目的是确定在按照与人类临床暴露方案相对应的较低静脉内(IV)剂量给予时,米诺环素在暂时性中脑动脉闭塞模型(TMCAO)中是否能有效减少梗塞面积。方法对大鼠进行90分钟的TMCAO。在TMCAO后4、5或6小时开始静脉注射米诺环素或生理盐水安慰剂。在TMCAO后24小时,使用2,3,5-三苯基四唑氯化物(TTC)脑染色和神经学评分评估进行梗塞体积和神经功能测试。对米诺环素治疗的大鼠进行了药代动力学研究和血液动力学监测。结果当在TMCAO后4小时给药时,米诺环素3 mg / kg和10 mg / kg IV剂量可有效减少梗死面积。在3 mg / kg的剂量下,米诺环素可使梗塞面积减少42%,而10 mg / kg则使梗塞面积减少56%。剂量为10 mg / kg的米诺环素可在5小时时显着减少40%的梗塞面积,而3 mg / kg剂量可显着减少34%的梗塞面积。在6小时的时间范围内,梗塞减轻的趋势不明显。在4小时的3 mg / kg和10 mg / kg的剂量下以及在5小时的10 mg / kg的剂量下,对米诺环素有利的神经学评分存在显着差异。米诺环素对血流动力学和生理变量没有明显影响。静脉给予3 mg / kg的米诺环素导致的血清水平与标准200 mg剂量后的人体水平相似。结论米诺环素在临床上合适的给药方案和至少4-5小时的治疗时间窗内的神经保护作用,考虑到开发用于治疗中风的药物,应考虑在人中进行I期试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号